Company news
Preveceutical Medical Inc (CSE:PREV) news
Preveceutical Medical Inc news releases on 6ix. Latest, Aug 4, 2026: PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
Press releases & updates
PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
August 4, 2026
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
July 27, 2026
PreveCeutical Announces Extension of Non-Brokered Private Placement
May 19, 2026
PreveCeutical Medical : Closes Initial Tranche of Non-Brokered Private Placement
May 12, 2026
PreveCeutical Adopts Semi-Annual Financial Reporting
April 1, 2026
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
March 30, 2026
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
February 25, 2026
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
February 9, 2026
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
December 4, 2025
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
November 26, 2025
CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)
November 24, 2025
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
November 20, 2025
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
November 20, 2025
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
October 30, 2025
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
October 10, 2025
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
September 19, 2025
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
September 5, 2025
PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics
September 4, 2025
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation
August 28, 2025
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
August 20, 2025
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
August 19, 2025
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
July 9, 2025
PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
June 30, 2025
PreveCeutical Announces Date for Annual General and Special Meeting
June 25, 2025
PreveCeutical Announces Non-Brokered Private Placement
June 11, 2025
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
June 2, 2025
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
May 26, 2025
PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement
May 22, 2025
PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
May 14, 2025
PreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private Placement
April 28, 2025
PreveCeutical Announces Up-Sized Non-Brokered Private Placement
April 13, 2025
PreveCeutical Announces Update to Non-Brokered Private Placement
April 2, 2025
PreveCeutical Announces Update to Private Placement
March 10, 2025
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
June 28, 2023
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
May 30, 2023
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
April 24, 2023
PreveCeutical Medical Announces Live Interactive Q&A Video Conference
April 20, 2023
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
April 4, 2023
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
March 20, 2023
PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
March 6, 2023
Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
February 21, 2023
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
February 7, 2023
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
January 25, 2023
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
January 23, 2023
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
January 17, 2023
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
January 12, 2023
PreveCeutical Signs Intercompany Sol-Gel License Agreement
January 9, 2023